Biologics CDMO Global Market to Observe Highest Growth of $36.54 Billion with an Excellent CAGR of 14.4% by 2028 | AbbVie Inc., Novartis AG, ICON PLC, Grifols SA, Lonza Group Ltd.

Overview and Scope
A biologics contract development and manufacturing organization (CDMO) is a service provider that supports pharmaceutical companies in the development and production of biologic drugs, which include vaccines, blood and blood components, allergens, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins.

Sizing and Forecast
The biologics CDMO market size has grown rapidly in recent years. It will grow from $18.44 billion in 2023 to $21.30 billion in 2024 at a compound annual growth rate (CAGR) of 15.4%.  The growth in the historic period can be attributed to rise in biologics development, cost efficiency and flexibility, focus on core competencies, regulatory compliance and quality assurance, globalization of pharmaceutical supply chains.

The biologics CDMO market size is expected to see rapid growth in the next few years. It will grow to $36.54 billion in 2028 at a compound annual growth rate (CAGR) of 14.4%.  The growth in the forecast period can be attributed to increasing demand for biologic therapies, emergence of biosimilars and biobetters, investments in biomanufacturing infrastructure, shift towards outsourcing complex processes, focus on supply chain resilience and risk mitigation, regulatory harmonization, and expedited approvals. Major trends in the forecast period include expansion of capabilities to offer end-to-end solutions, adoption of single-use technologies, integration of continuous manufacturing processes, emergence of specialized CDMOs.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Segmentation & Regional Insights
The biologics cdmo market covered in this report is segmented –
1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type:  Biologics, Biosimilars

North America was the largest region in the biologics CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

Major Driver Impacting Market Growth
The surge in demand for cell and genetic therapy is expected to propel the growth of the biologic CDMO market going forward. Cell and gene therapy are innovative medical approaches that utilize living cells or genetic material to address underlying disease causes at the cellular or genetic level, providing potential treatments for conditions that are difficult to manage or incurable with traditional pharmaceuticals. The demand for cell and gene therapy is rising due to their potential to offer innovative treatments for diseases by addressing underlying genetic or cellular causes. Biologic CDMOs provide expertise in handling living cells, viral vectors, and genetic material, facilitating safe and efficient production of cell and gene therapies while assisting biopharmaceutical companies in navigating regulatory requirements and technical challenges, thereby facilitating translation from research to clinical application. For instance, in January 2023, according to The American Society of Gene & Cell Therapy (ASGCT), a US-based primary professional membership organization, the gene, cell, and RNA therapy pipeline saw 7% growth in 2022, reaching a total of 3,726 therapies in development. Of these, 55% are gene therapies, while 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Therefore, the surge in demand for cell and genetic therapy is driving the growth of the biologic CDMO market.

Key Industry Players
Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

The biologics cdmo market report table of contents includes:
1. Executive Summary
2. Biologics CDMO Market Report Structure
3. Biologics CDMO Market Trends And Strategies
4. Biologics CDMO Market – Macro Economic Scenario
5. Biologics CDMO Market Size And Growth
……
27. Biologics CDMO Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the trending research reports from TBRC:
https://topprnews.com/gluten-feed-market

https://topprnews.com/organic-feed-market

https://topprnews.com/organic-pigments-market

https://goodprnews.com/rapeseed-oil-market

https://goodprnews.com/gluten-feed-market

https://goodprnews.com/manufactured-soil-market

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info

Healthcare Blog: https://healthcareresearchreports.com

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model